Streetbeat News

DHAI

DIH Holding US Inc

Industry

Surgical and Medical Instrument Manufacturing

Open

1.15

Mkt cap

41M

Volume

278K

High

1.24

P/E Ratio

-3.66

52-wk high

3.67

Low

1.11

Div yield

N/A

52-wk low

0.72

DIH Holding US, Inc. (NASDAQ:DHAI) has appointed Shepherd Center as a DIH Center of Excellence to enhance rehabilitation outcomes and drive advancements in patient recovery.

Portfolio Pulse from

December 23, 2024 | 12:15 pm

DIH Holding US, Inc. (NASDAQ:DHAI) has appointed Sheltering Arms Institute as a DIH Center of Excellence, enhancing its presence in the healthcare sector by partnering with top-tier providers for innovative patient recovery solutions.

Portfolio Pulse from

December 16, 2024 | 9:30 pm

DIH Holding US, Inc. (NASDAQ:DHAI) announced its Q2 2025 financial results and restated its Q1 2024 results due to revenue recognition issues for two devices sold in June 2024.

Portfolio Pulse from

November 14, 2024 | 10:45 pm

DIH Holding projects its fiscal year 2025 gross revenue to be between $74 million and $77 million, indicating potential growth and financial health.

Portfolio Pulse from Benzinga Newsdesk

August 19, 2024 | 8:37 pm

DIH Holding reported an improved EPS of $(0.02) compared to $(0.12) YoY, with revenue increasing to $16.19M from $13.05M. Despite a net loss, the company showed significant revenue growth and reduced losses.

Portfolio Pulse from Benzinga Newsdesk

August 19, 2024 | 8:37 pm

DIH reported a 24% year-over-year increase in Q1 revenue, reaching $16.2 million.

Portfolio Pulse from Benzinga Newsdesk

August 19, 2024 | 8:34 pm

DIH Holding US projects its FY25 gross revenue to be between $74 million and $77 million, indicating a 15%-20% growth over FY24.

Portfolio Pulse from Benzinga Newsdesk

July 15, 2024 | 9:36 pm

DIH Holding US reported a Q4 EPS of $(0.16), a significant decline from $0.19 last year. Revenue also decreased to $19.35M from $21.55M in the same period last year.

Portfolio Pulse from Benzinga Newsdesk

July 15, 2024 | 9:35 pm

12 health care stocks showed significant movements in Thursday's pre-market session. CNS Pharma (CNSP) saw the highest gain, rising 109.5%, while Gain Therapeutics (GANX) experienced the largest decline, falling 15.5%.

Portfolio Pulse from Benzinga Insights

July 05, 2024 | 2:59 pm

The article highlights the performance of 12 healthcare stocks during Tuesday's after-market session. Notable gainers include Reshape Lifesciences (RSLS), Dermata Therapeutics (DRMA), and Shuttle Pharmaceuticals (SHPH). Significant losers include Sharecare (SHCR), Reneo Pharmaceuticals (RPHM), and Sharps Technology (STSS).

Portfolio Pulse from Benzinga Insights

May 28, 2024 | 8:31 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.